Posts tagged Doug Loe
Echelon starts Theralase at speculative buy

Echelon Wealth Partners initiated coverage of Theralase Technologies (TSXV:TLT) with a “speculative buy” rating and one-year price target of 90 cents. The stock closed at 47 cents on Sept. 1.

Read More
Echelon starts Profound Medical at buy

Echelon Wealth Partners initiated coverage of Profound Medical (OTCQX:PRFMF; TSXV:PRN) with a “buy” rating and one-year price target of $4. The stock closed at 78 cents on March 14.

Read More
Echelon ups Neovasc price target to $3.25

Echelon Wealth Partners raised its price target for Neovasc (NASDAQ:NVCN) to $3.25 from $1.25 after the company sold its PeriPatch processing operations to Boston Scientific (NYSE:BSX). The stock closed at 86 cents on Dec. 2.

Read More
Echelon ups RepliCel price target to $2.15

Echelon Wealth Partners raised its price target for RepliCel Life Sciences (TSX-V:RP) to $2.15 from $1.50 after the company closed a unit offering that will add about $4.1-million in net cash to its balance sheet. The stock closed at $1.03 on Monday.

“The recapitalization provides funds to drive [RepliCel’s hair follicle-derived] non-bulbar dermal sheath cell platform forward with renewed vigor,” writes analyst Doug Loe, noting that he expects interim six-month data from a Phase 1/2 Achilles tendinosis/RCT-01 study by yearend.

Read More
Echelon starts Medical Facilities at buy

Echelon Wealth Partners initiated coverage of Medical Facilities (TSX:DR) with a “buy” rating and one-year price target of $22.50. The stock closed at $21.50 on Monday.

Medical Facilities (MFC) is a physician-owned specialty surgical hospital and ambulatory surgery center owner-operator.

Read More